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Aim: To assess the associations of age and diagnosis with visual ratings of medial
temporal lobe atrophy (MTA), parietal atrophy (PA), global cortical atrophy (GCA), and
white matter hyperintensities (WMH) and to investigate their clinical value in a large
memory clinic cohort.
Methods: We included 2,934 patients (age 67± 9 years; 1,391 [47%] female; MMSE 24
± 5) from the Amsterdam Dementia Cohort (1,347 dementia due to Alzheimer’s disease
[AD]; 681 mild cognitive impairment [MCI]; 906 controls with subjective cognitive decline).
We analyzed the effect of age, APOE e4 and diagnosis on visual ratings using linear
regression analyses. Subsequently, we compared diagnostic and predictive value in three
age-groups (<65 years, 65–75 years, and >75 years).
Results: Linear regression analyses showed main effects of age and diagnosis and an
interaction age∗diagnosis for MTA, PA, and GCA. For MTA the interaction effect indicated
steeper age effects in MCI and AD than in controls. PA and GCA increased with age in
MCI and controls, while AD patients have a high score, regardless of age. For WMH we
found a main effect of age, but not of diagnosis. For MTA, GCA and PA, diagnostic value
was best in patients <65 years (optimal cut-off: ≥1). PA and GCA only discriminated
in patients <65 years and MTA in patients <75 years. WMH did not discriminate at all.
Taking into account APOE did not affect the identified optimal cut-offs. When we used
these scales to predict progression in MCI using Cox proportional hazard models, only
MTA (cut-off ≥2) had any predictive value, restricted to patients >75 years.
Conclusion: Visual ratings of atrophy and WMH were differently affected by age and
diagnosis, requiring an age-specific approach in clinical practice. Their diagnostic value
seems strongest in younger patients.
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INTRODUCTION
The current diagnostic criteria for mild cognitive impairment
(MCI) and dementia due to Alzheimer’s disease (AD) advise to
apply biomarkers such as MRI features, to identify patients with
(underlying) AD pathology (Dubois et al., 2007, 2014; Albert
et al., 2011; McKhann et al., 2011). The criteria do not specify
how MRI features should be measured, what cut-offs should be
used and whether a patient’s age should be taken into account
(Frisoni et al., 2011). Studies demonstrating discriminatory value
of atrophy, such as medial temporal lobe atrophy (MTA), parietal
atrophy (PA) and global cortical atrophy (GCA) in AD, often
use automatic quantitative MRI analysis (van de Pol et al., 2006;
Sluimer et al., 2008; Henneman et al., 2009a; Trzepacz et al.,
2014). However, these analyses are time consuming hence hard
to apply in daily clinical practice. A feasible way of applying
MRI features in daily practice is to use established visual rating
scales for atrophy measures and vascular white matter changes
(Scheltens et al., 1992, 1995; Wattjes et al., 2009).
The presence of MTA has been shown to differentiate
patients with dementia due to AD from controls and to predict
progression to dementia in MCI patients (Scheltens et al., 1992;
Jack et al., 2002; Korf et al., 2004; Vos et al., 2012; Clerx et al.,
2013; Ferreira et al., 2015). However, medial temporal lobe
atrophy also occurs in normal aging (Jernigan et al., 2001; van de
Pol et al., 2006; Barkhof et al., 2007). To discriminate both young
and old controls from AD, an average score of the left and right
sides of MTA ≥ 1 has been proposed for patients <75 years and
MTA ≥ 1.5 for patients >75 years (Scheltens et al., 1992, 1995;
Schoonenboom et al., 2008). Recently two studies, based on the
same cohort, have suggested to increase the cut-off for patients
<75 years to MTA ≥ 1.5, for patients >75 years to MTA ≥ 2
and to add a specific cut-off of MTA ≥ 2.5 for patients aged >85
years (Pereira et al., 2014; Ferreira et al., 2015). Since these studies
used patients with amean age of 75, it remains uncertain what the
optimal cut-off in younger patients would be.
In younger patients, PA is increasingly recognized as an
important feature of AD (Koedam et al., 2010). Rating PA
improves the distinction of early onset AD patients from younger
controls, but seems to be less suited to separate older AD patients
from older controls (Lehmann et al., 2012; O’Donovan et al.,
2013). No age-specific cut-offs have yet been suggested (Koedam
et al., 2011; Ferreira et al., 2015). Only one study assessed the
diagnostic value of combining MTA with PA, but this study did
not take age into account (Ferreira et al., 2015). Being affected
by parietal atrophy as well, the GCA scale has a lot of overlap
with the PA scale. However, no cut-offs for the use of this scale
as a diagnostic or predictive marker exist (Pasquier et al., 1996;
Scheltens et al., 1997; Henneman et al., 2009b; Fjell et al., 2013).
Particularly in older patients, dementia pathology is often
mixed including neurodegenerative and vascular changes.
Therefore, in addition to measures of atrophy, it is common
practice to estimate the extent of small vessel disease (SVD),
such as white matter hyperintensities (WMH) in the diagnostic
workup (van der Flier et al., 2004; Kester et al., 2014). A recent CT
study showed an unexpected low percentage of WMH in elderly
patients (Claus et al., 2015). It has been suggested that WMH
may predict progression in the MCI stage, but other studies have
found no such effect (Prins et al., 2013; Mortamais et al., 2014).
TheWMH severity can be rated using Fazekas’ scale, but optimal
cut-offs for separating controls from AD taking into account age
have not been reported (Fazekas et al., 1987). Details regarding
the afore mentioned scales can be found in Table 1.
The aim of our study was to explore the effect of age on
the diagnostic value of visual ratings of MTA, PA, GCA, and
WMH for discriminating controls from AD and for predicting
progression to dementia in MCI in a very large memory clinic
cohort (van der Flier et al., 2014). Second, we evaluated the effect
of APOE genotype. Our ultimate goal is to provide practical
support to clinicians to improve the effective incorporation of
MRI visual ratings scale in daily practice.
METHODS
Subjects
We included 2,934 patients from the Amsterdam Dementia
Cohort who had visited the Alzheimer center between 2000 and
2015 (van der Flier et al., 2014). Of these patients, 906 were
diagnosed with subjective cognitive decline (SCD), who served
as controls, 681 with MCI and 1,347 with AD. Subjects were
included if MRI and mini mental state examination (MMSE;
Folstein et al., 1975), performed within 6 months of baseline
diagnosis, were available. The local medical ethical committee
approved the study, according to the declaration of Helsinki. All
patients provided written informed consent for their clinical data
to be used for research purposes.
Clinical Assessment
At baseline, patients received a standardized and multi-
disciplinary work-up, including medical history, physical,
neurological and neuropsychological examination, MRI and
laboratory tests. Cognitive functions are assessed with a
standardized test battery, including the MMSE and Cambridge
cognitive examination for global cognitive decline (Folstein
et al., 1975; Derix et al., 1991). For memory we use the visual
association test (VAT) and Rey auditory verbal learning task
(Saan and Deelman, 1986; Lindeboom et al., 2002). For language
we use VAT naming and category fluency (Lindeboom et al.,
2002; Van der Elst et al., 2006). For attention and executive
functions we use the trail making test A and B and the digit
span (Reitan, 1958; Lindeboom and Matto, 1994). More details
can be found in our cohort paper (van der Flier et al., 2014).
Diagnoses were made in a multidisciplinary consensus meeting
(van der Flier et al., 2014). Patients were labeled as SCD when
the cognitive complaints could not be confirmed by cognitive
testing and criteria for MCI, dementia or any other neurological
or psychiatric disorder known to cause cognitive complaints
were not met. MCI was diagnosed using Petersen’s criteria; in
addition all patients fulfilled the core clinical criteria of the NIA-
AA guidelines for MCI (Petersen, 2004; Albert et al., 2011).
Patients were diagnosed with probable AD using the criteria
of the National Institute for Neurological and Communicative
Diseases Alzheimer’s Disease and Related Disorders Association;
all patients also met the core clinical criteria of the National
Institute on Aging-Alzheimer’s Association guidelines for AD
(McKhann et al., 1984, 2011).
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TABLE 1 | Details on used visual ratings scale of MTA, PA, CGA, and WMH.
MTA (Scheltens et al., 1992, 1995) PA (Koedam et al., 2010)
Scale rated on coronal T1 images: Scale rated in sagittal and coronal T1 and axial flair images:
0 = normal 0 = no atrophy
1 = widened choroid fissure 1 = mild atrophy, opening of sulci
2 = increase of widened fissure, widening temporal horn, opening of other sulci 2 = moderate atrophy, volume loss gyri
3 = pronounced volume loss of hippocampus 3 = severe atrophy; knife blade
4 = end stage atrophy
Cut-offs described in literature:
:average left and right
Cut-offs described in literature:
:average left and right
- Original article by Scheltens (Scheltens et al., 1992) -Original article by Koedam (Koedam et al., 2011)
≥1 below 75 years sens 0.81 spec 0.67 ≥2, independent of age sens 0.58 spec 0.95
≥1.5 above 75 years - Ferreira (Ferreira et al., 2015)
- Pereira (Pereira et al., 2014) ≥1, independent of age sens and spec <0.65
≥1.5 below 75 years sens 0.79 spec 0.77
≥2 above 75 years sens 0.82 spec 0.75
- Ferreira (Ferreira et al., 2015)
≥2.5 above 85 years sens 0.60 spec 0.88
Rater reliability (Scheltens et al., 1995; Cavallin et al., 2012) Rater reliability (Koedam et al., 2011)
Inter-rater reliability: 0.72–0.84 Inter-rater reliability: 0.65–0.84
Intra-rater reliability: 0.83–0.94 Intra-rater reliability: 0.93–0.95
GCA (Pasquier et al., 1996) WMH (Fazekas et al., 1987)
Scale rated on axial flair images: Scale rated on axial flair images:
0 = no atrophy 0 = none or single (max 3) punctate lesions
1 = mild atrophy, opening of sulci 1 = multiple (≥3) punctate lesions
2 = moderate atrophy, volume loss gyri 2 = beginning confluent of lesions
3 = severe atrophy; knife blade 3 = large confluent lesions
No described cut-offs No described cut-offs
Rater reliability (Pasquier et al., 1996) No reported rater reliability
Inter-rater reliability: >0.6
Intra-rater reliability: >0.7
Sens, sensitivity; spec, specificity. Inter-rater and intra-rater reliability is presented as Cohen weighted Kappa.
Follow-Up
Follow-up for MCI patients took place by annual routine visits to
our memory clinic in which patient history, cognitive tests, and
a physical and neurologic examination were repeated. Follow-
up data were available in 464(68%) MCI patients, with a mean
duration of follow-up of 2.5 ± 1.7 years. Of these patients,
255(55%) remained stable, 161(35%) progressed to AD and
48(10%) progressed to another type of dementia.
MRI
Subjects were scanned with a standardized scan protocol on
1.0 T, 1.5 T, and 3.0 T whole body MRI systems as part
of their diagnostic work-up. Over time, the core protocol
remained comparable and always included 3DT1 with coronal
slices and FLAIR with axial slices. Details on acquisition
parameters per scanner can be found in Supplementary Table
1. All scans were visually rated by a trained rater after they
had completed the required training and obtained a weighted
kappa of at least 0.80 for MTA, 0.60 for GCA, and 0.70 for
Fazekas, and subsequently evaluated in a consensus meeting
with our experienced neuroradiologist. The raters were blinded
for diagnosis. Visual rating of MTA was performed on oblique
coronal T1-weighted images according to the 5-point (range 0–4)
Scheltens scale from the average score of the left and right sides
(Scheltens et al., 1992, 1995). PA was rated using the posterior
cortical atrophy scale (range 0–3), using T1 and FLAIR weighted
images viewed in sagittal, axial and coronal planes, computing
an average score of the left and right sides (Koedam et al., 2010,
2011; Lehmann et al., 2013). Global cortical atrophy (GCA) was
assessed visually on axial FLAIR images (range 0–3) (Pasquier
et al., 1996). The degree of white matter hyperintensities severity
was rated on axial FLAIR images using Fazekas’ scale (range 0–3)
(Fazekas et al., 1987). More details can be found in Table 1.
APOE Genotyping
DNA was isolated from 10 ml of EDTA blood. APOE
genotype was determined with the light cycler APOE
mutation detection method (Roche diagnostics GmbH,
Mannheim, Germany). According to APOE e4 status, patients
were dichotomized into carriers (hetero- and homozygous)
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and non-carriers. APOE status was available for 2410(82%)
subjects.
Statistical Analyses
For statistical analyses, we used SPSS version 20 (IBM, Armonk,
NY, USA). We compared visual ratings according to the baseline
diagnosis (controls, MCI and AD) using Kruskal-Wallis tests
and post-hoc Mann-Whitney U-tests. We used Spearman’s
correlations to assess correlations between visual rating
scales.
We used linear regression analyses to assess the combined
effect of age and diagnosis on visual ratings (using separate
models for each rating scale). As independent variables we
entered diagnosis (using dummy variables), age (continuous)
and the interaction terms for age∗diagnosis. In a second model
we additionally added APOE (dichotomized) as independent
variable and the interaction term age∗APOE. To confirm the age
effect on visual ratings we repeated the linear regression analyses
entering as independent variable, instead of diagnosis, MMSE
(continuous) and the interaction term for age∗MMSE. To allow
comparison of the different models, we report standardized betas
(st beta).
Subsequently, we created three age strata (<65 years, 65–
75 years and >75 years) and evaluated the diagnostic ability of
each visual rating scale to separate patients with dementia due to
AD from controls per age group. Sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV)
and the Youden index [(sensitivity + specificity)-1] (Youden,
1950) were calculated for different cut-off points in the three
age groups using cross tabulation. When we repeated the linear
regression analyses adding APOE, we found only an effect of
APOE e4 presence on the MTA scale. Therefore, we repeated
the evaluation of diagnostic ability for MTA only, stratifying for
APOE e4 carriers (controls vs. AD) and APOE e4 non-carriers
(controls vs. AD), excluding 524(18%) of subjects in which
APOE was not available. The highest Youden index indicated
the optimal cut-point, we took a Youden index >0.50 as a
minimum. For the scales showing a Youden index >0.50, we
assessed the effect of combining the scales at their optimal cut-off.
We created a new variable consisting of 4 levels: 1. normal MTA
and normal PA (reference group), 2. normal MTA and abnormal
PA, 3. abnormal MTA and normal PA, 4. abnormal MTA and
abnormal PA. This was also done for the combination of MTA
and GCA.
Finally, we assessed the predictive value of the visual
ratings for dementia due to AD in MCI patients, stratified
by age group. We used Cox proportional hazard models,
taking into account variability in time to follow up. Baseline
MTA, PA, CGA, and WMH were entered dichotomized,
in separate models, at the earlier derived optimal, age-
specific cut-offs and, in addition as continuous values. In a
separate model, we evaluated the combined effect of MTA
and PA and of MTA and GCA using the newly constructed
4 level variables, as described above. Event variable was
progression to dementia due to AD, excluding subjects with
progression to another type of dementia, and in another
model progression to all types of dementia. Sex was entered
as co-variate. HR with 95% confidence intervals (CI) are
presented.
A p < 0.05 was considered significant. Since we focus
on discriminatory and predictive value, rather than statistical
significance, we did not adjust for multiple comparisons.
RESULTS
Baseline Characteristics
Table 2 shows the baseline characteristics of the total population.
Patients with MCI and AD were older and had more WMH
than controls. Patients with AD were more often female, more
often APOE e4 carrier, had the lowest MMSE score and highest
MTA, PA, and GCA compared to controls and MCI. When
we assessed correlations between the visual rating scales using
Spearman’s rho, we found the strongest correlation between PA
and GCA (r = 0.732) and the weakest correlation for WMH and
PA (r = 0.133; Supplementary Table 2).
Influence of Age and Diagnosis on Visual
Ratings
We used linear regression analyses to assess the combined effect
of age and diagnosis on each visual rating (Figure 1 and Table 3).
For MTA we found main effects of age and diagnosis. In addition
there was an interaction effect for age∗diagnosis, indicating a
somewhat steeper age effect in patients with MCI and AD than
in controls. For PA and GCA, we found main effects of age and
diagnosis. In addition, there was an interaction effect for AD
age∗diagnosis, indicating that AD patients have a higher score,
regardless of their age, while in MCI and controls, PA and GCA
increased with age. For WMH we only found a main effect of
age but no main effect of diagnosis nor interaction between age
and diagnosis. When we added APOE and age∗APOE to the
model, we found a main effect of APOE onMTA indicating more
MTA in case of APOE e4 presence, and an interaction effect of
age∗APOE, indicating a steeper age effect in APOE non-carriers
TABLE 2 | Baseline characteristics of controls, MCI and AD patients in the
total group.
Control MCI AD
N 906 681 1347
Age 62 ± 9 69 ± 9 69 ± 9a
Female# 404 (45%) 271 (40%) 716 (53%)ab
MMSE 28 ± 2 26 ± 2 20 ± 5ab
Level of education 5 ± 1 5 ± 1 5 ± 1a
APOE e4 carrier# 281 (36%) 285 (54%) 729 (54%)ab
MTA 0.4 ± 0.6 1.0 ± 0.9 1.6 ± 0.9ab
PA 0.6 ± 0.7 0.9 ± 0.7 1.4 ± 0.7ab
GCA 0.4 ± 0.6 0.8 ± 0.7 1.2 ± 0.7ab
WMH 0.7 ± 0.7 1.1 ± 0.9 1.1 ± 0.9a
Values are mean ± standard deviation or n (%). Group differences between the different
diagnostic groups were estimated using Chi-quadrate test# and Kruskal-Wallis test and
post hoc Mann-Whitney U-tests when appropriate. Please note that although we report
mean ± standard deviation for the visual rating scales, we used non-parametric tests. aP
< 0.05 compared to control, bP < 0.05 compared to MCI.
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FIGURE 1 | Plots using linear regression analyses of MTA, PA, GCA, and WMH vs. age in controls, MCI and dementia due to AD, after correction for
gender. Y-as: respectively mean MTA (left + right/2), PA (left + right/2), GCA, and WMH, X-as: age in years, 95% confidence interval is presented by the gray area on
both sides of each line.
on MTA. However, in PA, GCA, and WMH we found no main
effect of APOE nor an interaction effect of age∗APOE.
When we repeated the linear regression analyses with MMSE
and age∗MMSE instead of diagnosis and age∗diagnosis, the same
age effects were found. Details can be found in Supplementary
Tables 3, 4.
Visual Ratings per Baseline Diagnosis and
Age Groups
Since there was a clear effect of age on visual ratings, we
categorized patients in three age strata; <65 years, 65–75 years
and >75 years. Figure 2 visualizes the mean score of each visual
rating scale in the different age strata, according to baseline
diagnosis. Group sizes for the diagnostic groups by age strata are
reported in the figure. For MTA, we found differences between
all diagnostic groups in each age group. For PA and GCA, we
found differences between all diagnostic groups in <65 years. In
addition, for GCA this was also found in the stratum 65–75 years.
For PA, in the age group 65–75 years, only AD differed from
SCD and MCI, while >75 years AD differed only from MCI. For
WMH we found differences between SCD and MCI and between
SCD and AD in age groups <65 years and, 65–75 years. There
were no differences between diagnostic groups in the >75 years
stratum.
Diagnostic Value of Visual Ratings to
Separate AD from Controls per Age Group
Based on the highest Youden index, we determined the optimal
cut-off for each rating scale in the total group and per age stratum
(Table 4). A cut-off of MTA ≥ 1 was optimal for the total group
and for <65 years and a cut-off MTA ≥ 1.5 for 65–75 years.
In the patients aged >75 years no satisfactory cut-off could be
derived. Both PA and GCA add sensitivity in the younger age
range, as for these scales we found a high sensitivity at the cost of
a lower specificity. A cut-off of an average PA ≥ 1 and GCA ≥ 1
were optimal for <65 years. PA and GCA did not discriminate
in the older age groups. WMH did not sufficiently discriminate
between groups at all. When we repeated the cross-tabulation for
finding the optimal cut-off for MTA in APOE carriers and non-
carriers results only changed marginally and optimal cut-offs
were comparable (Supplementary Table 5).
Since MTA, PA, and GCA all had diagnostic value in the
age group <65 years, we evaluated if the combination of these
scales improved their diagnostic value. Table 5 shows that a
Frontiers in Aging Neuroscience | www.frontiersin.org 5 May 2017 | Volume 9 | Article 117
Rhodius-Meester et al. Age, Diagnosis and MRI Ratings
FIGURE 2 | Clustered bars showing mean MTA, PA, GCA, and WMH scores for age group according to baseline diagnosis. Y-as: respectively mean MTA
(left + right/2), PA (left + right/2), GCA, and WMH, X-as: age group, 95% confidence interval is presented by the error bars, *indicates significant difference between
diagnostic groups, using Kruskal-Wallis tests and post-hoc Mann-Whitney U-tests.
TABLE 3 | Combined effect of age and diagnosis on visual ratings.
MTA PA GCA WMH
St beta p St beta p St beta p St beta p
Constant −1.55 <0.001 −1.94 <0.001 −1.86 <0.001 −1.33 <0.001
Sex, male 0.07 <0.001 0.08 <0.001 0.08 <0.001 −0.06 <0.001
Age 0.30 <0.001 0.46 <0.001 0.45 <0.001 0.37 <0.001
DIAGNOSIS
MCI −0.32 <0.001 0.39 005 0.18 <0.001 0.11 0.443
AD 0.07 0.563 1.78 <0.001 1.11 <0.001 −0.17 0.227
INTERACTION
Age*MCI 0.49 <0.001 −0.36 0.014 −0.09 0.508 −0.02 0.912
Age*AD 0.45 <0.001 −1.48 <0.001 −0.75 <0.001 0.26 0.081
R square 0.43 0.27 0.33 0.19
F 367.98 183.04 236.90 116.93
df regression 6 6 6 6
df residual 2,927 2,926 2,927 2,927
Linear regression analyses were used, using separate models for each rating scale. As
independent variables we entered diagnosis (using dummy variables), age (continuous)
and the interaction terms for age*diagnosis. St beta: standardized coefficients beta, p,
p-value; F, Fisher; df, degrees of freedom.
combination of MTA with PA or GCA provides a very sensitive
and specific indication for AD in the age group <65 years,
especially when both ratings are abnormal. In case of one normal
and one abnormal rating, the Youden index remained at or below
0.50, and did not add over the application of MTA or GCA/PA
alone.
Prediction Ability of Visual Ratings per Age
Group in MCI
Finally, we assessed the predictive value of the visual ratings for
dementia due to AD inMCI patients. Details of the demographics
and visual ratings of these MCI patients are provided in Table 6.
In the patients 65–75 years there was more WMH in the stable
MCI as compared to progressive MCI patients, in patients
>75 years MTA differed between stable and progressive MCI
patients. Results of Cox proportional hazards models are shown
in Table 7. Using age-specific cut-offs derived from the controls-
AD comparisons, predictive value of MTA was strongest in the
oldest MCI patients. PA, GCA, and WMH were not associated
with progression to dementia due to AD in any of the age
groups. Combination of the visual ratings resulted in a predictive
effect for an abnormal MTA with and abnormal PA in the age
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TABLE 4 | Discriminatory value of different cut-off points of MTA, PA, GCA, and WMH for differentiating AD from controls in total population and in three
age groups.
Cut-off point Total <65 years 65–75 years >75 years
n = 2253 n = 1047 n = 774 n = 432
PPV NPV sens spec Youden PPV NPV Sens Spec Youden PPV NPV Sens Spec Youden PPV NPV Sens Spec Youden
MTA
≥0.5 0.76 0.83 0.92 0.58 0.50 0.70 0.85 0.85 0.71 0.56 0.78 0.80 0.95 0.42 0.37 0.83 0.42 0.97 0.10 0.07
≥1 0.84 0.74 0.82 0.76 0.58 0.85 0.79 0.70 0.90 0.60 0.82 0.64 0.84 0.62 0.46 0.85 0.46 0.94 0.22 0.16
≥1.5 0.93 0.61 0.60 0.94 0.54 0.96 0.68 0.42 0.98 0.40 0.94 0.53 0.61 0.92 0.53 0.91 0.42 0.81 0.62 0.43
≥2 0.95 0.52 0.40 0.97 0.37 0.97 0.61 0.21 1.00 0.19 0.96 0.43 0.40 0.96 0.36 0.93 0.32 0.65 0.77 0.42
≥2.5 0.97 0.46 0.21 0.99 0.20 1.00 0.58 0.08 1.00 0.08 0.98 0.37 0.19 0.99 0.18 0.96 0.26 0.41 0.92 0.33
≥3 0.97 0.43 0.11 1.00 0.11 1.00 0.56 0.03 1.00 0.03 1.00 0.34 0.09 1.00 0.09 0.96 0.22 0.25 0.95 0.20
PA
≥1 0.74 0.73 0.87 0.55 0.42 0.70 0.84 0.84 0.71 0.55 0.73 0.54 0.87 0.33 0.20 0.82 0.18 0.91 0.09 0.01
≥2 0.87 0.51 0.40 0.91 0.31 0.90 0.67 0.40 0.97 0.37 0.86 0.39 0.36 0.88 0.24 0.86 0.19 0.46 0.58 0.04
≥3 0.87 0.41 0.04 0.99 0.03 0.95 0.56 0.04 1.00 0.04 0.76 0.32 0.03 0.98 0.01 0.89 0.18 0.05 0.97 0.02
GCA
≥1 0.78 0.75 0.86 0.64 0.50 0.75 0.82 0.79 0.79 0.58 0.77 0.61 0.86 0.46 0.32 0.83 0.29 0.93 0.13 0.06
≥2 0.90 0.49 0.34 0.94 0.28 0.98 0.63 0.26 1.00 0.26 0.88 0.38 0.29 0.92 0.21 0.87 0.23 0.51 0.65 0.16
≥3 0.96 0.41 0.02 1.00 0.02 1.00 0.56 0.01 1.00 0.01 0.84 0.32 0.01 1.00 0.01 1.00 0.19 0.04 1.00 0.04
WMH
≥1 0.67 0.53 0.74 0.45 0.19 0.50 0.61 0.54 0.57 0.11 0.70 0.40 0.80 0.29 0.09 0.82 0.17 0.89 0.10 0.01
≥2 0.77 0.45 0.26 0.88 0.14 0.57 0.56 0.09 0.95 0.06 0.79 0.36 0.31 0.83 0.14 0.83 0.19 0.43 0.60 0.03
≥3 0.85 0.42 0.08 0.98 0.06 0.54 0.56 0.02 0.99 0.01 0.88 0.33 0.08 0.98 0.06 0.89 0.19 0.16 0.91 0.07
The results are calculated using cross tabulation. Youden index = (sensitivity + specificity) −1. Bold values are the cut-off values that showed the best differentiation.
Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value.
TABLE 5 | Sensitivity and specificity for the combination of MTA and PA
and for the combination of MTA and GCA for differentiating AD from
controls in age group <65 years.
N Sens Spec Youden
COMBINED MTA AND PA: MTA≥1, PA ≥1
MTA and PA normal 407 Ref Ref Ref
MTA normal/PA abnormal 252 0.77 0.72 0.49
MTA abnormal/PA normal 80 0.58 0.92 0.50
MTA and PA abnormal 308 0.90 0.94 0.84
COMBINED MTA AND GCA: MTA≥1, GCA ≥ 1
MTA and GCA normal 465 Ref Ref Ref
MTA normal/GCA abnormal 194 0.69 0.81 0.50
MTA abnormal/GCA normal 91 0.57 0.92 0.49
MTA and GCA abnormal 297 0.86 0.94 0.80
A new variable using 4 levels was created, using only the cut-offs with a Youden
index> 0.50 from Table 2. Sensitivity and specificity are calculated using cross tabulation.
Youden index = (sensitivity + specificity) −1. Bold values are the combinations that
showed the best differentiation. Sens, sensitivity; Spec, specificity.
groups <65 years and 65–75 years. Combination of an abnormal
MTA with an abnormal GCA resulted in the same effect in
the age group <65 years. When we entered visual rating scales
as continuous measures, MTA and WMH were slightly more
predictive in older patients, GCA in younger patients. When we
repeated the Cox analyses with lower cut-offs only HR of MTA
improved slightly in the age group >75 years. When we used
progression to any type dementia as outcome measure, results
changed only marginally. Details are shown in Supplementary
Table 6.
DISCUSSION AND CONCLUSION
In this very large memory cohort with a broad age range,
we studied the combined effect of age and diagnosis on the
visual ratings of atrophy and WMH in controls, MCI and
AD. This resulted in three main findings. First, we found an
independent effect of age and diagnosis on MTA, resulting in
different diagnostic and predictive value in the three age groups.
Second, age and diagnosis had a different effect on PA and
GCA, providing unequivocal support for their diagnostic value,
specifically in younger patients. And third, for WMH we found
hardly any diagnostic or predictive value, while this measure was
strongly related to age.
Our first finding that MTA is equally affected by age and
diagnosis, is consistent with former studies (Launer et al., 1995;
Bastos Leite et al., 2004; van de Pol et al., 2006; Barkhof et al.,
2007). Earlier studies have suggested age-specific cut-offs for
MTA (Scheltens et al., 1992; Koedam et al., 2011; Duara et al.,
2013; Pereira et al., 2014; van de Pol and Scheltens, 2014; Ferreira
et al., 2015). We found the best diagnostic performance in
MTA in the youngest group, with an identified optimal cut-
off of MTA ≥ 1, which is the same as the original article but
lower than the cut-off of MTA ≥ 1.5 advised by two recent
articles (Scheltens et al., 1992, 1995, 1997; Barber et al., 1999;
Pereira et al., 2014; Ferreira et al., 2015). Younger subjects
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TABLE 6 | Baseline visual ratings of MCI patients according to diagnosis
at follow-up by age group.
Stable MCI at FU Progression to AD at FU
<65 years N 105 43
Age 58 ± 5 59 ± 4
MTA 0.4 ± 0.6 0.5 ± 0.6
GCA 0.4 ± 0.6 0.6 ± 0.6
PA 0.5 ± 0.6 0.5 ± 0.5
WMH 0.7 ± 0.8 0.8 ± 0.8
65–75 years N 120 79
Age 70 ± 3 70 ± 3
MTA 0.8 ± 0.7 0.9 ± 0.8
GCA 0.7 ± 0.6 0.8 ± 0.6
PA 0.8 ± 0.7 0.9 ± 0.7
WMH 1.3 ± 0.9 0.8 ± 0.8*
>75 years N 30 39
Age 78 ± 2 78 ± 2
MTA 1.0 ± 0.7 1.7 ± 0.9*
GCA 1.0 ± 0.6 1.2 ± 0.6
PA 1.2 ± 0.8 1.2 ± 0.7
WMH 1.3 ± 0.8 1.3 ± 0.9
Values are mean ± standard deviation. Group differences were estimated using Mann-
Whitney test. Please note that although we report mean± standard deviation for the visual
rating scales, we used non-parametric tests. *Difference between MCI and dementia due
to AD at follow up with p < 0.05.
should not have medial temporal atrophy at all; at an age
<65 years even a MTA score of 1 is suspicious. This finding
might be explained by differences in study populations. Our
cohort contains a large subgroup <65 years, consisting of 1,047
controls and AD with a mean age of 58 ± 5 years. In former
studies assessing the effect of age on MTA, average age of the
so-called younger groups was much higher. Also our average
MMSE is higher than in most studies, suggesting less advanced
disease. The optimal cut-off of MTA ≥ 1.5 for 65–75 years was
similar to recent studies (Schoonenboom et al., 2008; Pereira
et al., 2014; Ferreira et al., 2015). For the subjects aged >75
years sensitivity and specificity when applying a MTA ≥ 1.5
(sensitivity 0.81; specificity 0.62) or a MTA ≥ 2 (sensitivity
0.65, specificity 0.78) are comparable to previous studies, but
the low Youden index indicates that diagnostic performance
is modest. When we repeated our linear regression analysis
including APOE, we found, comparable to earlier studies, more
MTA in APOE carriers and a stronger age effect on MTA in non-
carriers (Pereira et al., 2014; Ferreira et al., 2015). Apparently
the presence of APOE e4 results in more affected hippocampal
region (van der Flier et al., 2011; van de Pol and Scheltens,
2014). The effect of APOE on MTA was subtle however and did
not lead to different optimal cut-offs. This is in line with the
fact that APOE genotype is generally not used in the diagnostic
work-up of AD.
When we attempted to predict progression to AD dementia
in patients with MCI, MTA had strongest predictive value in
the oldest group >75 years. PA, GCA, and WMH showed
TABLE 7 | Cox proportional hazard models; influence of MTA, PA, GCA,
and WMH and combination of MTA/PA and MTA/GCA on progression of
MCI to dementia due to AD in the three age groups.
<65 years 65–75 years >75 years
n = 148 n = 199 n = 148
MTA MTA ≥ 1 MTA ≥ 1.5 MTA ≥ 2
2.0 (1.0–4.0) 1.3 (0.8–2.2) 2.2 (1.1–4.6)
PA PA ≥ 1 PA ≥ 2 PA ≥ 2
1.6 (0.9–3.0) 1.7 (0.9–3.1) 1.1 (0.5–2.2)
GCA GCA ≥1 GCA ≥ 1 GCA ≥ 2
2.1 (1.1–3.9) 1.7 (1.0–2.8) 1.4 (07–3.1)
WMH WMH ≥1 WMH ≥2 WMH ≥ 3
1.2 (0.6–2.3) 0.4 (0.2–0.8) 2.8 (0.9–8.7)
MTA AND PA MTA ≥ 1/PA ≥1 MTA ≥1.5/PA ≥ 2 MTA ≥2/PA ≥ 2
- MTA and PA normal Ref Ref Ref
- MTA normal/ PA abnormal 1.4 (0.7–2.9) 1.4 (0.7–3.2) 1.1 (0.4–2.6)
- MTA abnormal/ PA normal 1.4 (0.7–2.6) 1.1 (0.8–1.4) 1.5 (0.9–2.2)
- MTA and PA abnormal 1.3 (1.0–1.8) 1.4 (1.0–1.9) 1.3 (0.9–1.9)
MTA AND GCA MTA≥1/GCA≥ 1 MTA≥ 1.5/GCA≥ 1 MTA≥2/GCA≥2
- MTA and GCA normal Ref Ref Ref
- MTA normal/ GCA abnormal 1.8 (0.8–3.8) 1.5 (0.8–2.6) 1.5 (0.5–4.1)
- MTA abnormal/ GCA normal 1.3 (0.7–2.5) 0.8 (0.4–1.6) 1.6 (1.0–2.5)
- MTA and GCA abnormal 1.5 (1.1–2.0) 1.2 (1.0–1.6) 1.3 (0.9–1.9)
Data are presented as hazard ratio (HR) (95% CI). Cox proportional hazard models
compared progression to AD with non-converters (= stable MCI at follow-up). Time
variable was time to follow-up in years; state variable was progression to AD. The
visual ratings were entered dichotomized at the optimal cut-off as was derived from
classifying controls from dementia due to AD (Table 2). For the combination of MTA/PA
and MTA/GCA a new 4 level variable as presented in Table 3, was used. Sex was entered
as co-variate. Bold values are the HR’s with p < 0.05.
no predictive value. In addition, the predictive value of MTA
in the younger patients was limited. This was an unexpected
result, as previous studies have shown predictive ability for
MTA and PA, especially in younger subjects (Korf et al., 2004;
Staekenborg et al., 2009; Lehmann et al., 2012, 2013; Prins
et al., 2013; Ferreira et al., 2015). However, in our study, the
MCI subjects aged <65 years were younger than in previous
studies and they had lower MTA scores. In addition, younger
patients were less likely to show clinical progression than older
patients (<65:28% vs. 65–75:44% vs. >75:56%), resulting in less
power. Apparently MCI patients <65 years constitute a different
patient category than older MCI patients. It is conceivable that
the prototypical patient with MCI due to AD, is a patient that
develops a typical, hippocampal type of AD, with an age-at-
onset of about 75 years. Younger subjects with the earliest stages
of cognitive decline tend to have an atypical presentation, a
longer doctors-delay because of misdiagnosis and suffer from a
larger penalty on stigmatizing them with MCI (Koedam et al.,
2010; Barnes et al., 2015). As a result, younger subjects with
AD, often present to a memory clinic already at dementia stage,
which may result in a bias for the MCI population in this
age group. In older subjects, MCI might be better recognized,
which could explain the predictive value of MTA in this group.
Also, in the patients 65–75 years there was more WMH in
the stable MCI as compared to progressive MCI patients. This
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suggests that the WMH, rather than AD, could be the cause
for their cognitive decline, explaining why this specific group
remained stable. Another reason for the low predictive value
might be our choice to use the cut-offs derived from controls-AD
comparison. One could argue that patients with MCI might have
subtler atrophy rates, being earlier in the disease trajectory, thus
requiring more sensitive cut-offs. When we repeated the Cox-
analyses with lower cut-offs however, predictive values did not
improve.
Our second finding concerned the different effects of age
and diagnosis on PA and GCA. Previous studies have shown
that PA ratings have diagnostic value in early onset AD but do
not help the separation of late onset AD from older controls
(Koedam et al., 2011; Lehmann et al., 2012, 2013; O’Donovan
et al., 2013). To date this has not been reflected by age-specific
cut-offs for PA and GCA. To our knowledge, only one study
assessed age-specific cut-offs for PA, finding a low diagnostic
value, yet advising a cut-off PA ≥1 for all age groups (Ferreira
et al., 2015). In our study we found that patients with AD have
a high score on PA and GCA regardless of age, while controls
and MCI show increased PA and GCA scores with increasing
age. These findings resulted in a high diagnostic value for both
PA and GCA in patients <65 years, but no value of PA and
GCA for patients>65 years. The optimal cut-off for both atrophy
measures was a rating of ≥1. The original paper proposed a
higher cut-off PA ≥2, resulting in a high specificity at the cost
of a low sensitivity (Koedam et al., 2011). With a lower cut-
off ≥1 we now found a reverse pattern in the age-group <65
years, with a high sensitivity at the cost of a lower specificity.
An additional finding of abnormal MTA greatly adds specificity
to PA. In this subgroup of patients <65 years, a combination
of an abnormal PA and MTA resulted in very high sensitivity
and specificity, hence this should be regarded as alarming. In
the preparation of this study, we also used a classification tree to
improve the utility of combining visual ratings. However, this tree
only added improvement in discriminating controls from AD
for both MTA with PA in the age group <65 years. We decided
to leave these analyses out of the paper, as the more complex
modeling did not add to our message. Furthermore, since our
aim was to evaluate the visual ratings as a clinician would, we
chose to use as simple as statistics as possible, reflecting clinical
practice.
In our study, we found WMH mainly to be affected by
age, but not by diagnosis. Various studies have advocated
a synergistic effect of SVD and AD pathology on cognitive
decline, while other studies have shown that SVD in AD
was related to age and vascular risk factors, comparable to
individuals without AD (Kester et al., 2014; Mortamais et al.,
2014; Spies et al., 2014; Benedictus et al., 2015; Claus et al.,
2015; Prins and Scheltens, 2015). Yet, in all these studies the
diagnostic value of WMH for separating AD from controls
has not been addressed. We found no diagnostic utility for
WMH in discriminating AD from controls, which cannot be
explained by the relatively young age of our study sample,
since even in the oldest age stratum, WMH did not have any
discriminatory value. Assessing WMH in the diagnostic work-
up remains important, because of the known negative effect of
WMH on many outcomes, such as functional decline, (lacunar)
infarcts, depression and mortality (Pantoni et al., 2005; van
der Flier et al., 2005; Inzitari et al., 2007; Verdelho et al.,
2010; Firbank et al., 2012). Furthermore, presence of WMH
indicates a possible treatable cause in order to prevent further
deterioration (Basile et al., 2006; Prins and Scheltens, 2015).
These findings do not oppose the possible interaction of SVD
and AD. Since WMH in this study was equally severe in aging
controls, one might argue that dementia at older age is by
definition “mixed.” Perhaps in older subjects, having WMH, less
AD damage is needed to develop dementia (van der Flier et al.,
2004; Mortamais et al., 2014). These age effects persisted when
we usedMMSE score instead of clinical diagnosis which confirms
our finding.
These findings have several clinical implications. The value
of the visual ratings of atrophy and WMH all differ across the
age-groups. This makes it of utmost importance to take into
account the age of the patients when using MRI in diagnostic
workup. Especially in the younger patients MTA and PA/GCA
have diagnostic value; atrophy at an age <65 is a bad sign.
By combining MTA with PA/GCA, the value even increases.
Older age reduces the value of rating scales substantially, in
older patients it is harder to separate age-effect from AD-
effect. These findings are in line with the classical Braak model
for MTA (Braak et al., 2006). However, the findings for PA
are not in line with Braak, since especially young subjects
showed severe PA only in AD cases, which is not observed
in controls and MCI, whereas this difference disappears in
increasing age. This suggests a separate pathological stageing-
model for younger patients may be warranted (Jagust et al.,
2008; Fjell et al., 2013). In this patient group, the use of visual
ratings should be used to rule-out AD in case of no atrophy
rather than proving inclusive evidence for AD when there is
atrophy. Perhaps in the future more automated measures will be
able to distinguish pathological from age-adequate brain aging,
being able to pick up more subtle effects (Koikkalainen et al.,
2016). Automatic quantification methods of brain atrophy, and
other modalities such as FDG-PET, also have the advantage
of providing objective measures, independent of the expertise
of the clinician, whereas visual ratings are a subjective visual
interpretation. Furthermore, these automatic methods are able
to extract more information and combine information, for
example on WMH and atrophy, and provide an estimate
of the underlying neurodegenerative disease. Visual rating of
MRI’s have the advantage however that they are more feasible
in daily clinical practice. Automatic quantification methods
are dependent on scan protocol and quality, whereas visual
ratings can be applied to images acquired with less advanced
scanners. Also these automatic methods often require costly
and time-consuming software-programs, while visual ratings
can be applied in an instant, with the patient in front of the
clinician.
This study has several limitations. First, the lack of
neuropathological confirmation of diagnosis. Especially in
elderly patients, with comorbid SVD, atrophy might also be the
result of WMH or hippocampal sclerosis and not of amyloid
pathology (Barkhof et al., 2007). Due to this we might have
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selected patients that have been misclassified with AD. However,
in this study we found a similar degree of WMH in all elderly
subjects, regardless of diagnosis, diminishing the importance of
specifying the etiology as mixed or not. Second, we used SCD as
controls, although we cannot exclude the possibility that these
patients had underlying AD. We feel that the comparison of AD
with SCD patients is a clinically relevant comparison however,
as this is the differential diagnosis that a clinician has to make
every day. Furthermore, underlying AD can also not be excluded
in “pure” controls, as it is known that roughly one third of
normal elderly harbors AD pathology (Chetelat et al., 2010; Vos
et al., 2013). Third, the mean follow-up of 2.5 ± 1.7 years could
imply that MCI patients, who remained stable during this period,
might still progress to dementia after longer follow up. Fourth,
in our clinical work-up clinicians are not blinded for the MRI
results. This might have resulted in bias. The effect of the MRI
results on diagnosis might have also changed throughout the
time due to changing insights in use of biomarkers. However,
all diagnoses were made in our multidisciplinary consensus
meeting, in which the clinical characteristics of the patient and
the cognitive profile on neuropsychological testing is leading.
A final limitation could be the use of different scanners with
increasing field strength throughout the time. This could also
be regarded as a strength however, as the visual ratings have the
advantage that they are robust for scanner differences and easy
to use.
Among the strengths of the current study is our harmonized
diagnostic protocol according to which all patients were analyzed.
All patients were selected from the samememory clinic. The large
sample size and the broad age spectrum ranging from 45 to 95
makes these results robust. Furthermore, the scans were rated
by experienced researchers after they had completed the required
training (van der Flier et al., 2014).
To conclude, visual ratings are of use in daily practice, but
should be interpreted with caution and with reference to a
patients’ age. The current research criteria advise the use of
MTA in the diagnostic work-up for AD, but do not specify the
amount of atrophy or the effect of age (Dubois et al., 2007,
2014). This study shows that MTA is strongly influenced by age
and that age related cut-offs are needed. PA and GCA seem
to be of equal use for the diagnostic workup in patients <65
years, and their information is incremental to the information
in the MTA scale. Taking into account age-specific cut-offs
and characteristics of each visual rating scale, use of visual
rating scales for MRI can enhance recognition of AD for
either diagnostic or research purposes, especially in younger
patients.
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